June 2024
Gilead’s Magrolimab Ineffective, Linked to Increased Risk of Death in MDS Patients
Gilead, Magrolimab, MDS, Myelodysplastic Syndrome, Cancer Treatment, Clinical Trials, Safety Concerns
Gilead’s Magrolimab Linked to Increased Risk of Death in Blood Cancer Patients
Gilead, Magrolimab, Blood Cancer, Increased Risk of Death, ENHANCE Study
Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery
Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.
Western In-Licensing Deals with Chinese Companies: Focus on Disease Areas and Drug Types
, In-licensing deals, Chinese pharmaceutical companies, Western pharmaceutical companies, Disease areas, Drug types, Cross-border partnerships, Biopharma, Licensing trends,
Revolutionizing Clinical Trials: Leveraging AI for Enhanced Efficiency and Accuracy
Artificial Intelligence, Clinical Trials, Data Analysis, Patient Recruitment, Personalized Medicine, AI-Powered Tools, Medical Research, Efficiency, Accuracy
Ipsen and Genfit Secure FDA Approval for Iqirvo, a Breakthrough Treatment for Primary Biliary Cholangitis
Ipsen, Genfit, Iqirvo, FDA approval, primary biliary cholangitis, liver disease, Intercept, Ocaliva
Huntington’s Disease Clinical Trials: Updates on Dalzanemdor and Tominersen
Huntington’s disease, clinical trials, dalzanemdor, tominersen, cognitive impairment, RNA-based therapy, NMDA receptor modulator, Phase 2 and Phase 3 studies
Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence
Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.
GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59
GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.
Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial
Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses